VONTOBEL FINANCIAL PRODUCTS GMBH | Market Closed - Boerse Frankfurt Warrants 19:04:45 25/06/2024 BST | ||
| 96.65 JPY | +0.25% |
|
| Current month | -1.86% | ||
| 1 month | -0.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 96.65 | +0.25% |
| 24/06/24 | 96.41 | +0.70% |
| 21/06/24 | 95.74 | +0.12% |
| 20/06/24 | 95.63 | +0.02% |
| 19/06/24 | 95.61 | +0.06% |
Real-time Boerse Frankfurt Warrants
Last update June 25, 2024 at 07:04 pm
More quotesStatic data
| Product type | Aktienanleihen |
|---|---|
| Buy / Sell | CALL |
| Underlying | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| Issuer | 
Vontobel
|
| WKN | VM58VD |
| ISIN | DE000VM58VD4 |
| Date issued | 04/12/2023 |
| Strike | 4,132 ¥ |
| Maturity | 04/12/2024 (162 Days) |
| Parity | 0.83 : 1 |
| Emission price | 100 ¥ |
| Emission volume | N/A |
| Settlement | Beides |
| Currency | JPY |
Technical Indicators
| Highest since issue | 101 ¥ |
|---|---|
| Lowest since issue | 94.58 ¥ |
Company Profile
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
-
Ratings for Takeda Pharmaceutical Company Limited
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Takeda Pharmaceutical Company Limited
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,176
JPY
Average target price
4,744
JPY
Spread / Average Target
+13.61%
- Stock Market
- Certificates
- Certificat
